Results 231 to 240 of about 26,268,555 (308)

Loss of AMBRA1 activates MAPK and angiogenesis signaling pathways in melanoma cells

FEBS Open Bio, EarlyView.
Loss of AMBRA1 in melanoma cells activates multiple oncogenic pathways associated with tumor progression. Transcriptomic and protein network analyses revealed that AMBRA1 depletion enhances MAPK/ERK signaling, angiogenesis, TGF‐β/EMT signaling, and Wnt/axon guidance pathways.
Milad Ibrahim, Marco Corazzari, Iman Osman, Jane Armstrong, Noel Carter   +4 more
wiley   +1 more source

The Contribution of Dostarlimab to First-Line Treatment of Advanced or Recurrent Endometrial Cancer in Spain: A Multi-Criteria Decision Analysis Approach. [PDF]

J Clin Med
Barretina-Ginesta MP, Lorente CM, Maximiano C, Díez R, Ec-McDa Group, Ariznavarreta A, Calvo A, Soler F.   +7 more
europepmc   +1 more source

Effects of IGFBP4 deficiency on human preadipocyte proliferation and differentiation through the IGF1R/AKT pathway

FEBS Open Bio, EarlyView.
IGFBP4 knockdown (KD) impairs preadipocyte proliferation and is associated with IGF1R protein downregulation and attenuated AKT phosphorylation. The mechanisms by which IGFBP4 KD influences the IGF1R/AKT signaling pathway involve newly synthesized proteins and lysosomal degradation pathways. Created in BioRender.
Yujia Guo, Sandy Richter, Christoph Bach, Wieland Kiess, Anna Kirstein, Diana Le Duc, Antje Garten   +6 more
wiley   +1 more source

Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2- Metastatic Breast Cancer. [PDF]

Cancer Epidemiol Biomarkers Prev
Vidal GA, Katz J, Sadetsky N, Dabrowski EC, Kaufman PA, Verret W, Stwalley B, Kalinsky K.   +7 more
europepmc   +1 more source

From energy provision to protein synthesis: Tunnelling nanotubes as mediators of intercellular metabolic cooperation in cancer

FEBS Open Bio, EarlyView.
The cytoskeleton‐mediated transport of mitochondria via tunnelling nanotubes restores respiration, increases ATP production, rescues cells from apoptosis, activates the AKT/mTOR signalling pathway, promotes cell migration and invasiveness, contributes to cancer progression and treatment resistance.
Stanislava Martínková, Jan Trnka
wiley   +1 more source

Aumolertinib Versus Osimertinib as First-Line Treatment for EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Multicenter Study. [PDF]

Int J Cancer
Wang J, Qi P, Li J, Wang N, Fu C, Liu L, Li S, Li X, Hou X, Qiao H.   +9 more
europepmc   +1 more source

Yeast Gcn2 retains activity following humanization of its auto‐phosphorylation region

FEBS Open Bio, EarlyView.
Using Saccharomyces cerevisiae as a model to study Gcn2 activation and regulation is limited by the lack of antibodies detecting phosphorylated Gcn2. To overcome this, we engineered Gcn2‐HsC, a yeast Gcn2 variant recognizable by commercial anti‐human phospho‐GCN2 antibodies.
Reuben A. Anderson, Anja H. Schiemann, Evelyn Sattlegger   +2 more
wiley   +1 more source

Conversion Surgery for Advanced Gastric Cancer According to First-Line Treatment Strategy: A Single-Center Experience with a Focused Review of the Literature. [PDF]

Cancers (Basel)
Kinoshita J, Doden K, Hayashi K, Matsui R, Saito H, Watanabe M, Tsuji T, Yamamoto D, Inaki N.   +8 more
europepmc   +1 more source

MagmaFlow: A desktop platform for artificial intelligence‐driven expression analysis

FEBS Open Bio, EarlyView.
MagmaFlow is a free, no‐code platform for gene expression analysis. It generates interactive volcano plots, links genes to literature, pathways, and diseases, prioritizes candidates using millions of publications, identifies affected biological processes, builds network diagrams, and exports publication‐ready figures and reports for macOS and Windows ...
Carlos E. Buss, Ao Li, Eduardo H. Gilglioni, Mayank Bansal, Sumeet Pal Singh, Latifa Bakiri, Alessandra K. Cardozo, Esteban N. Gurzov   +7 more
wiley   +1 more source

First-Line Treatment of Chronic Lymphocytic Leukemia in Italy: Real-World Evidence on Utilization, Outcomes, and Healthcare Costs. [PDF]

Clinicoecon Outcomes Res
Perrone V, Innao V, Mazzoni S, Cappuccilli M, Andretta M, Bartolini F, Chinellato A, Dell'Orco S, Ferrante F, Lombardi R, Pagliaro R, Ubertazzo L, Valpondi P, Degli Esposti L.   +13 more
europepmc   +1 more source